NeuroSense Therapeutics Ltd. NRSN
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) is a CNS/neurology/psychiatry drug developer. Its lead program, PrimeC (extended-release ciprofloxacin + celecoxib), is in Phase 2 for Amyotrophic lateral sclerosis (ALS).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PrimeC | ALS (Phase 2b PARADIGM completed incl. 12-month open-label extension) | small molecule | Phase 2 |
| Ciprofloxacin/celecoxib combination | Alzheimer's disease (patent granted; no clinical trial described in extract) | small molecule | Pre-clinical |
Recent results and decisions
- Oct 19, 2026n/a NeuroSense filed a U.S. patent application covering use of PrimeC (ciprofloxacin and celecoxib) to treat traumatic brain injury, including concussion, blast-related injury, and chronic traumatic encephalopathy.
The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term consequences, such as chronic traumatic encephalopathy (CTE).
Filing - Jun 29, 2026met Phase 2b PARADIGM met primary efficacy endpoint: statistically significant TDP-43 reduction vs placebo at Day 180 (p=0.0421), sustained at Day 540 (p<0.001).
At Day 180, the pre-specified primary endpoint timepoint, PrimeC produced a statistically significant reduction in TDP-43 versus placebo (p=0.0421).
Filing - Nov 24, 2025n/a FDA completed review of IND amendment and authorized initiation of the pivotal Phase 3 PARAGON trial of PrimeC in ALS (300 patients, 2:1, 12-month placebo-controlled); first patient dependent on securing resources.
the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational New Drug (IND) amendment application and authorized the Company to initiate the pivotal Phase 3 clinical trial
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.